{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:33:51Z","timestamp":1792719231597,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T00:00:00Z","timestamp":1345161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/nrc3343","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T05:58:49Z","timestamp":1345183129000},"page":"599-612","source":"Crossref","is-referenced-by-count":609,"title":["The role of mutations in epigenetic regulators in myeloid malignancies"],"prefix":"10.1038","volume":"12","author":[{"given":"Alan H.","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,17]]},"reference":[{"key":"BFnrc3343_CR1","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd, J. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325\u20134336 (2002).","journal-title":"Blood"},{"key":"BFnrc3343_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk, R. F. et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909\u20131918 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3343_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/00062752-200107000-00001","volume":"8","author":"DG Gilliland","year":"2001","unstructured":"Gilliland, D. G. Hematologic malignancies. Curr. Opin. Hematol. 8, 189\u2013191 (2001).","journal-title":"Curr. Opin. Hematol."},{"key":"BFnrc3343_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2007.02.006","volume":"128","author":"AD Goldberg","year":"2007","unstructured":"Goldberg, A. D., Allis, C. D. & Bernstein, E. Epigenetics: a landscape takes shape. Cell 128, 635\u2013638 (2007).","journal-title":"Cell"},{"key":"BFnrc3343_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/epi.11.73","volume":"3","author":"C Florean","year":"2011","unstructured":"Florean, C., Schnekenburger, M., Grandjenette, C., Dicato, M. & Diederich, M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 3, 581\u2013609 (2011).","journal-title":"Epigenomics"},{"key":"BFnrc3343_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079\u20131089 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3343_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature06008","volume":"448","author":"TS Mikkelsen","year":"2007","unstructured":"Mikkelsen, T. S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553\u2013560 (2007).","journal-title":"Nature"},{"key":"BFnrc3343_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nri2991","volume":"11","author":"H Cedar","year":"2011","unstructured":"Cedar, H. & Bergman, Y. Epigenetics of haematopoietic cell development. Nature Rev. Immunol. 11, 478\u2013488 (2011).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrc3343_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature09367","volume":"467","author":"H Ji","year":"2010","unstructured":"Ji, H. et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467, 338\u2013342 (2010).","journal-title":"Nature"},{"key":"BFnrc3343_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ng.708","volume":"42","author":"J Borgel","year":"2010","unstructured":"Borgel, J. et al. Targets and dynamics of promoter DNA methylation during early mouse development. Nature Genet. 42, 1093\u20131100 (2010).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2007-09-113597","volume":"113","author":"J Faber","year":"2009","unstructured":"Faber, J. et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113, 2375\u20132385 (2009).","journal-title":"Blood"},{"key":"BFnrc3343_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13\u201327 (2010). A study demonstrating subclassification of AML through systematic methylation profiling.","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR13","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424\u20132433 (2010). Identification of DNMT3A mutations in AML by large-scale sequencing.","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3343_CR14","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol, F. et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J. Clin. Oncol. 29, 2889\u20132896 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3343_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jmb.2006.01.035","volume":"357","author":"H Gowher","year":"2006","unstructured":"Gowher, H. et al. Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase. J. Mol. Biol. 357, 928\u2013941 (2006).","journal-title":"J. Mol. Biol."},{"key":"BFnrc3343_CR16","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1038\/onc.2010.117","volume":"29","author":"Y Yamashita","year":"2010","unstructured":"Yamashita, Y. et al. Array-based genomic resequencing of human leukemia. Oncogene 29, 3723\u20133731 (2010).","journal-title":"Oncogene"},{"key":"BFnrc3343_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/ng.788","volume":"43","author":"XJ Yan","year":"2011","unstructured":"Yan, X. J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genet. 43, 309\u2013315 (2011).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3324\/haematol.2011.051581","volume":"97","author":"I Fried","year":"2012","unstructured":"Fried, I. et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 97, 246\u2013250 (2012).","journal-title":"Haematologica"},{"key":"BFnrc3343_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-12-387685-0.00007-X","volume":"101","author":"F Chedin","year":"2011","unstructured":"Chedin, F. The DNMT3 family of mammalian de novo DNA methyltransferases. Prog. Mol. Biol. Transl. Sci. 101, 255\u2013285 (2011).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"BFnrc3343_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nature05987","volume":"448","author":"SK Ooi","year":"2007","unstructured":"Ooi, S. K. et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714\u2013717 (2007).","journal-title":"Nature"},{"key":"BFnrc3343_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20060750","volume":"204","author":"Y Tadokoro","year":"2007","unstructured":"Tadokoro, Y., Ema, H., Okano, M., Li, E. & Nakauchi, H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J. Exp. Med. 204, 715\u2013722 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnrc3343_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2012","unstructured":"Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genet. 44, 23\u201331 (2012).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR23","first-page":"4075","volume":"62","author":"R Ono","year":"2002","unstructured":"Ono, R. et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 62, 4075\u20134080 (2002).","journal-title":"Cancer Res."},{"key":"BFnrc3343_CR24","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930\u2013935 (2009).","journal-title":"Science"},{"key":"BFnrc3343_CR25","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289\u20132301 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3343_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.391","volume":"41","author":"SM Langemeijer","year":"2009","unstructured":"Langemeijer, S. M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genet. 41, 838\u2013842 (2009). References 25 and 26 first identified TET2 mutations in myeloid malignancies.","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","volume":"29","author":"KH Metzeler","year":"2011","unstructured":"Metzeler, K. H. et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 29, 1373\u20131381 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3343_CR28","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496\u20132506 (2011). A large clinical study that reported the clinical implications of somatic mutations in epigenetic modifiers in MDS.","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3343_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","volume":"70","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab, O. et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 70, 447\u2013452 (2010).","journal-title":"Cancer Res."},{"key":"BFnrc3343_CR30","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","volume":"115","author":"FX Schaub","year":"2010","unstructured":"Schaub, F. X. et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115, 2003\u20132007 (2010).","journal-title":"Blood"},{"key":"BFnrc3343_CR31","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","volume":"116","author":"AE Smith","year":"2010","unstructured":"Smith, A. E. et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116, 3923\u20133932 (2010).","journal-title":"Blood"},{"key":"BFnrc3343_CR32","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1093\/nar\/gkh739","volume":"32","author":"V Valinluck","year":"2004","unstructured":"Valinluck, V. et al. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 32, 4100\u20134108 (2004).","journal-title":"Nucleic Acids Res."},{"key":"BFnrc3343_CR33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature10102","volume":"473","author":"WA Pastor","year":"2011","unstructured":"Pastor, W. A. et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473, 394\u2013397 (2011).","journal-title":"Nature"},{"key":"BFnrc3343_CR34","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/0008-5472.CAN-06-3123","volume":"67","author":"V Valinluck","year":"2007","unstructured":"Valinluck, V. & Sowers, L. C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 67, 946\u2013950 (2007).","journal-title":"Cancer Res."},{"key":"BFnrc3343_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cell.2011.03.022","volume":"145","author":"JU Guo","year":"2011","unstructured":"Guo, J. U., Su, Y., Zhong, C., Ming, G. L. & Song, H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423\u2013434 (2011).","journal-title":"Cell"},{"key":"BFnrc3343_CR36","doi-asserted-by":"publisher","first-page":"41991","DOI":"10.1074\/jbc.M106953200","volume":"276","author":"RJ Boorstein","year":"2001","unstructured":"Boorstein, R. J. et al. Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1. J. Biol. Chem. 276, 41991\u201341997 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3343_CR37","doi-asserted-by":"publisher","first-page":"12510","DOI":"10.1021\/ja0634829","volume":"128","author":"MT Bennett","year":"2006","unstructured":"Bennett, M. T. et al. Specificity of human thymine DNA glycosylase depends on N-glycosidic bond stability. J. Am. Chem. Soc. 128, 12510\u201312519 (2006).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnrc3343_CR38","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1126\/science.1210944","volume":"333","author":"YF He","year":"2011","unstructured":"He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303\u20131307 (2011).","journal-title":"Science"},{"key":"BFnrc3343_CR39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1101\/gad.2036011","volume":"25","author":"H Wu","year":"2011","unstructured":"Wu, H. et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev. 25, 679\u2013684 (2011).","journal-title":"Genes Dev."},{"key":"BFnrc3343_CR40","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.cell.2011.11.054","volume":"147","author":"O Yildirim","year":"2011","unstructured":"Yildirim, O. et al. Mbd3\/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147, 1498\u20131510 (2011).","journal-title":"Cell"},{"key":"BFnrc3343_CR41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nature10008","volume":"473","author":"G Ficz","year":"2011","unstructured":"Ficz, G. et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 473, 398\u2013402 (2011).","journal-title":"Nature"},{"key":"BFnrc3343_CR42","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.4161\/cc.10.15.16930","volume":"10","author":"H Wu","year":"2011","unstructured":"Wu, H. & Zhang, Y. Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells. Cell Cycle 10, 2428\u20132436 (2011).","journal-title":"Cell Cycle"},{"key":"BFnrc3343_CR43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839\u2013843 (2010).","journal-title":"Nature"},{"key":"BFnrc3343_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11\u201324 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR45","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","volume":"94","author":"O Kosmider","year":"2009","unstructured":"Kosmider, O. et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 94, 1676\u20131681 (2009).","journal-title":"Haematologica"},{"key":"BFnrc3343_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25\u201338 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR47","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","volume":"118","author":"Z Li","year":"2011","unstructured":"Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509\u20134518 (2011).","journal-title":"Blood"},{"key":"BFnrc3343_CR48","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058\u20131066 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3343_CR49","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","volume":"28","author":"G Marcucci","year":"2010","unstructured":"Marcucci, G. et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 28, 2348\u20132355 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3343_CR50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225\u2013234 (2010).","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739\u2013744 (2009).","journal-title":"Nature"},{"key":"BFnrc3343_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20092506","volume":"207","author":"S Gross","year":"2010","unstructured":"Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339\u2013344 (2010).","journal-title":"J. Exp. Med."},{"key":"BFnrc3343_CR53","doi-asserted-by":"publisher","first-page":"e1002781","DOI":"10.1371\/journal.pgen.1002781","volume":"8","author":"A Akalin","year":"2012","unstructured":"Akalin, A. et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 8, e1002781 (2012).","journal-title":"PLoS Genet."},{"key":"BFnrc3343_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17\u201330 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR55","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553\u2013567 (2010). References 54 and 55 identify the functional interaction between IDH1 and IDH2 mutations and TET enzymes.","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR56","unstructured":"Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 4 Jul 2012 (doi:10.1038\/nature11323)."},{"key":"BFnrc3343_CR57","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.sbi.2010.08.006","volume":"20","author":"MA McDonough","year":"2010","unstructured":"McDonough, M. A., Loenarz, C., Chowdhury, R., Clifton, I. J. & Schofield, C. J. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr. Opin. Struct. Biol. 20, 659\u2013672 (2010).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"BFnrc3343_CR58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","volume":"12","author":"R Chowdhury","year":"2011","unstructured":"Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463\u2013469 (2011).","journal-title":"EMBO Rep."},{"key":"BFnrc3343_CR59","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature10898","volume":"483","author":"P Koivunen","year":"2012","unstructured":"Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484\u2013488 (2012).","journal-title":"Nature"},{"key":"BFnrc3343_CR60","first-page":"LBA-4","volume":"118","author":"J-A Losman","year":"2011","unstructured":"Losman, J.-A., Lee, S., Koivunen, P., Looper, R. E. & Kaelin, W. G. Enantiomer-specific transformation by 2HG is linked to opposing effects on \u03b1-ketoglutarate-dependent dioxygenases. Blood (ASH Annual Meeting Abstracts) 118, LBA-4 (2011).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrc3343_CR61","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"BFnrc3343_CR62","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","volume":"22","author":"AP Bracken","year":"2003","unstructured":"Bracken, A. P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323\u20135335 (2003).","journal-title":"EMBO J."},{"key":"BFnrc3343_CR63","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624\u2013629 (2002).","journal-title":"Nature"},{"key":"BFnrc3343_CR64","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1126\/science.1165395","volume":"322","author":"S Varambally","year":"2008","unstructured":"Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695\u20131699 (2008).","journal-title":"Science"},{"key":"BFnrc3343_CR65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genet. 42, 181\u2013185 (2010).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR66","doi-asserted-by":"publisher","first-page":"20980","DOI":"10.1073\/pnas.1012525107","volume":"107","author":"CJ Sneeringer","year":"2010","unstructured":"Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980\u201320985 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3343_CR67","doi-asserted-by":"publisher","first-page":"10657","DOI":"10.1158\/0008-5472.CAN-07-2498","volume":"67","author":"J Yu","year":"2007","unstructured":"Yu, J. et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67, 10657\u201310663 (2007).","journal-title":"Cancer Res."},{"key":"BFnrc3343_CR68","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genet. 42, 722\u2013726 (2010).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR69","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ng.620","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genet. 42, 665\u2013667 (2010).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR70","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/ni876","volume":"4","author":"IH Su","year":"2003","unstructured":"Su, I. H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nature Immunol. 4, 124\u2013131 (2003).","journal-title":"Nature Immunol."},{"key":"BFnrc3343_CR71","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","volume":"119","author":"J Score","year":"2012","unstructured":"Score, J. et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms. Blood 119, 1208\u20131213 (2012).","journal-title":"Blood"},{"key":"BFnrc3343_CR72","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1038\/bcj.2011.31","volume":"1","author":"M Brecqueville","year":"2011","unstructured":"Brecqueville, M. et al. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J. 1, e33 (2011).","journal-title":"Blood Cancer J."},{"key":"BFnrc3343_CR73","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510 (2012).","journal-title":"Nature"},{"key":"BFnrc3343_CR74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157\u2013163 (2012).","journal-title":"Nature"},{"key":"BFnrc3343_CR75","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1101\/gad.13.20.2691","volume":"13","author":"J Lessard","year":"1999","unstructured":"Lessard, J. et al. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 13, 2691\u20132703 (1999).","journal-title":"Genes Dev."},{"key":"BFnrc3343_CR76","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/ncomms1623","volume":"3","author":"A Herrera-Merchan","year":"2012","unstructured":"Herrera-Merchan, A. et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nature Commun. 3, 623 (2012).","journal-title":"Nature Commun."},{"key":"BFnrc3343_CR77","first-page":"1930","volume":"88","author":"MM Le Beau","year":"1996","unstructured":"Le Beau, M. M. et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88, 1930\u20131935 (1996).","journal-title":"Blood"},{"key":"BFnrc3343_CR78","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli, P. et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118, 5227\u20135234 (2011).","journal-title":"Blood"},{"key":"BFnrc3343_CR79","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature01587","volume":"423","author":"IK Park","year":"2003","unstructured":"Park, I. K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302\u2013305 (2003).","journal-title":"Nature"},{"key":"BFnrc3343_CR80","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1084\/jem.20111709","volume":"209","author":"H Oguro","year":"2012","unstructured":"Oguro, H. et al. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J. Exp. Med. 209, 445\u2013454 (2012).","journal-title":"J. Exp. Med."},{"key":"BFnrc3343_CR81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature08966","volume":"465","author":"JC Scheuermann","year":"2010","unstructured":"Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243\u2013247 (2010).","journal-title":"Nature"},{"key":"BFnrc3343_CR82","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2011.58","volume":"25","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab, O. et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25, 1200\u20131202 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR83","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/leu.2010.144","volume":"24","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab, O., Kilpivaara, O., Patel, J., Busque, L. & Levine, R. L. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 24, 1656\u20131657 (2010).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR84","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","volume":"118","author":"KH Metzeler","year":"2011","unstructured":"Metzeler, K. H. et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118, 6920\u20136929 (2011).","journal-title":"Blood"},{"key":"BFnrc3343_CR85","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4161\/cc.11.1.18475","volume":"11","author":"L Aravind","year":"2012","unstructured":"Aravind, L. & Iyer, L. M. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle 11, 119\u2013131 (2012).","journal-title":"Cell Cycle"},{"key":"BFnrc3343_CR86","unstructured":"Abdel-Wahab, O. et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (in the press)."},{"key":"BFnrc3343_CR87","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2009-07-230698","volume":"115","author":"CL Fisher","year":"2010","unstructured":"Fisher, C. L. et al. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115, 38\u201346 (2010).","journal-title":"Blood"},{"key":"BFnrc3343_CR88","first-page":"405","volume":"118","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab, O. et al. ASXL1 mutations promote myeloid transformation through inhibition of PRC2-mediated gene repression. Blood (ASH Annual Meeting Abstracts) 118, 405 (2011).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrc3343_CR89","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/ng.910","volume":"43","author":"T Wiesner","year":"2011","unstructured":"Wiesner, T. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genet. 43, 1018\u20131021 (2011).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR90","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genet. 43, 1022\u20131025 (2011).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR91","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nature Rev. Cancer 7, 823\u2013833 (2007). An excellent review on MLL-associated leukaemias and related epigenetic biology.","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3343_CR92","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbmt.2008.10.010","volume":"15","author":"A Tefferi","year":"2009","unstructured":"Tefferi, A., Levine, R. L. & Kantarjian, H. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Biol. Blood Marrow Transplant. 15, 114\u2013119 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrc3343_CR93","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature08448","volume":"461","author":"MA Dawson","year":"2009","unstructured":"Dawson, M. A. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1\u03b1 from chromatin. Nature 461, 819\u2013822 (2009).","journal-title":"Nature"},{"key":"BFnrc3343_CR94","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","volume":"19","author":"F Liu","year":"2011","unstructured":"Liu, F. et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19, 283\u2013294 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR95","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/ncb2135","volume":"13","author":"DS Griffiths","year":"2011","unstructured":"Griffiths, D. S. et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nature Cell Biol. 13, 13\u201321 (2011).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3343_CR96","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"H de The","year":"2010","unstructured":"de The, H. & Chen, Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Rev. Cancer 10, 775\u2013783 (2010).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3343_CR97","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood.V85.4.1083.bloodjournal8541083","volume":"85","author":"JD Licht","year":"1995","unstructured":"Licht, J. D. et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85, 1083\u20131094 (1995).","journal-title":"Blood"},{"key":"BFnrc3343_CR98","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1101\/gad.512009","volume":"23","author":"H Boukarabila","year":"2009","unstructured":"Boukarabila, H. et al. The PRC1 Polycomb group complex interacts with PLZF\/RARA to mediate leukemic transformation. Genes Dev. 23, 1195\u20131206 (2009).","journal-title":"Genes Dev."},{"key":"BFnrc3343_CR99","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccr.2007.04.009","volume":"11","author":"R Villa","year":"2007","unstructured":"Villa, R. et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513\u2013525 (2007).","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR100","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1073\/pnas.102583199","volume":"99","author":"AB Dash","year":"2002","unstructured":"Dash, A. B. et al. A murine model of CML blast crisis induced by cooperation between BCR\/ABL and NUP98\/HOXA9. Proc. Natl Acad. Sci. USA 99, 7622\u20137627 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3343_CR101","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nature09171","volume":"466","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466, 765\u2013768 (2010).","journal-title":"Nature"},{"key":"BFnrc3343_CR102","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nm.2187","volume":"16","author":"MG Kharas","year":"2010","unstructured":"Kharas, M. G. et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature Med. 16, 903\u2013908 (2010).","journal-title":"Nature Med."},{"key":"BFnrc3343_CR103","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann, V. et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25, 557\u2013560 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR104","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/leu.2010.65","volume":"24","author":"J Boultwood","year":"2010","unstructured":"Boultwood, J. et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 24, 1139\u20131145 (2010).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR105","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","volume":"117","author":"H Makishima","year":"2011","unstructured":"Makishima, H. et al. CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 117, e198\u2013e206 (2011).","journal-title":"Blood"},{"key":"BFnrc3343_CR106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/leu.2011.253","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi, A. et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26, 475\u2013480 (2012).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR107","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/leu.2011.139","volume":"25","author":"C Roche-Lestienne","year":"2011","unstructured":"Roche-Lestienne, C. et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia 25, 1661\u20131664 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR108","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/ncomms1826","volume":"3","author":"MT Bocker","year":"2012","unstructured":"Bocker, M. T. et al. Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nature Commun. 3, 818 (2012).","journal-title":"Nature Commun."},{"key":"BFnrc3343_CR109","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2009.47","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi, A. et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23, 905\u2013911 (2009).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR110","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","volume":"114","author":"O Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144\u2013147 (2009).","journal-title":"Blood"},{"key":"BFnrc3343_CR111","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/leu.2011.77","volume":"25","author":"F Stegelmann","year":"2011","unstructured":"Stegelmann, F. et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25, 1217\u20131219 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR112","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/leu.2011.82","volume":"25","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab, O. et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25, 1219\u20131220 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR113","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/leu.2010.113","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi, A. et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24, 1302\u20131309 (2010).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR114","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1182\/blood-2010-02-270926","volume":"116","author":"CL Green","year":"2010","unstructured":"Green, C. L. et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3\/ITD status. Blood 116, 2779\u20132782 (2010).","journal-title":"Blood"},{"key":"BFnrc3343_CR115","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","volume":"118","author":"CL Green","year":"2011","unstructured":"Green, C. L. et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118, 409\u2013412 (2011).","journal-title":"Blood"},{"key":"BFnrc3343_CR116","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2011","unstructured":"Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genet. 44, 23\u201331 (2011).","journal-title":"Nature Genet."},{"key":"BFnrc3343_CR117","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/leu.2011.44","volume":"25","author":"MJ Walter","year":"2011","unstructured":"Walter, M. J. et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25, 1153\u20131158 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR118","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/leu.2011.10","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann, V. et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 25, 877\u2013879 (2011).","journal-title":"Leukemia"},{"key":"BFnrc3343_CR119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","volume":"20","author":"KM Bernt","year":"2011","unstructured":"Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66\u201378 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrc3343_CR120","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1172\/JCI25546","volume":"116","author":"AM Dorrance","year":"2006","unstructured":"Dorrance, A. M. et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J. Clin. Invest. 116, 2707\u20132716 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrc3343_CR121","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1200\/JCO.2002.09.088","volume":"20","author":"K Dohner","year":"2002","unstructured":"Dohner, K. et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J. Clin. Oncol. 20, 3254\u20133261 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc3343_CR122","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak, M. L. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study. Blood 96, 4075\u20134083 (2000).","journal-title":"Blood"},{"key":"BFnrc3343_CR123","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood.V82.12.3705.3705","volume":"82","author":"HJ Super","year":"1993","unstructured":"Super, H. J. et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82, 3705\u20133711 (1993).","journal-title":"Blood"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc3343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3343","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:34:43Z","timestamp":1684467283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc3343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,17]]},"references-count":123,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFnrc3343"],"URL":"https:\/\/doi.org\/10.1038\/nrc3343","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,17]]}}}